What is the regulatory status of Selank?

Selank regulatory status: Unapproved (approved in Russia) in the United States; WADA status not on prohibited list; research level russian clinical trials in gad. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For sourcing and quality-control use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does Selank's half-life affect dosing?

Selank has a plasma half-life of CNS effect lasts hours; plasma short, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under daily for 2-4 week courses dosing at 300 mcg per spray; 2-3 sprays daily per dose explains the typical onset timeline for sourcing and quality-control endpoints.

What are the safety considerations for Selank?

Excellent. No reported dependence. Mild nasal irritation possible. For sourcing and quality-control use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Selank's CNS effect lasts hours; plasma short pharmacokinetic profile and intranasal/subq administration route influence the side-effect profile in predictable ways.

What class of compound is Selank?

Selank is classified as a Tuftsin-derived heptapeptide anxiolytic. Within this class, alternative names and analogues include TP-7, Threonyl-Lysyl-Prolyl-Arginyl-Prolyl-Glycyl-Proline. The class-level pharmacology shapes both the clinical applications and the safety profile; the sourcing / quality / procurement literature treats Selank alongside its class peers when evaluating relative merits.

What is the evidence base for Selank?

Selank's evidence base sits at russian clinical trials in gad. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Home/ Compounds/ Selank

Selank

Sourcing Guide

Sourcing Selank from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.

Sourcing / Quality / Procurement Applications

Mass Spectrometry VerificationLyophilisation QualityReconstitution GuideLot VariabilityRegulatory Sourcing

Key Takeaways

Procurement lens: Selank sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 751 Da.
Mechanism: Modulates GABA-A receptor systems indirectly.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

For procurement of Selank, the relevant QC framework covers analytical purity (HPLC), structural identity (mass spec), microbiological safety (endotoxin), and stoichiometric correctness where applicable. Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. The subsections below address each QC layer and the vendor-tier landscape.

Vendor tier comparison and price discipline

Three vendor tiers operate in the Selank market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for Selank is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 751 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

COA evaluation and red flags

Acceptable Selank certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Sourcing / Quality / Procurement Applications

BAC Water Sourcing

Sourcing Selank for bac water sourcing use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Cold Chain

For users targeting cold chain, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

COA Review

Pharmaceutical-grade compounded Selank is the lowest-risk sourcing path for coa review use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Red Flag Detection

Sourcing Selank for red flag detection use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray; 2-3 sprays daily	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray; 2-3 sprays daily	4–6 weeks initial cycle
Sourcing Guide focus	Intranasal	300 mcg per spray; 2-3 sprays daily	Daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray; 2-3 sprays daily	Ongoing with periodic pauses

Dose timing for Selank is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

Selank + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Selank's mechanism in sourcing / quality / procurement protocols.
Selank + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Selank's mechanism in sourcing / quality / procurement protocols.
Selank + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Selank's mechanism in sourcing / quality / procurement protocols.
Selank + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Selank's mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (approved in Russia) Research: Russian clinical trials in GAD

Excellent. No reported dependence. Mild nasal irritation possible.

Lens-specific safety considerations for sourcing / quality / procurement use of Selank: Excellent. No reported dependence. Mild nasal irritation possible. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank — anxiolytic activity and tuftsin-derived peptides

PMID 16240858

Supporting

Selank in generalised anxiety disorder

PMID 21443549

Selank vs Related Peptides

Compound	Profile	Onset	Best For
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

What should I check on a Selank COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

Storage protocol?

Lyophilised: −20°C for 18–24 months. Reconstituted with bacteriostatic water: 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Cold-chain shipping is preferred for purchases; insulated packaging without active cooling is acceptable for shorter transit windows.

Visual quality inspection?

Lyophilised Selank should be a uniform white powder adherent to the vial wall or as a freeze-dried cake. Discoloration, residue on the rubber septum, or particulate matter in the lyophilised product are reasons to request replacement before reconstituting.

Vendor red flags?

Six markers: (1) no lot-specific COAs available, (2) HPLC purity only, no copper or stoichiometry assay where applicable, (3) no physical address or regulatory disclosure, (4) no cold-chain shipping option, (5) no refund policy for failed-QC lots, (6) therapeutic claims about research material. Multiple flags = walk away.

What is the standard dosing protocol for Selank?

Conventional Selank dosing is 300 mcg per spray; 2-3 sprays daily daily for 2-4 week courses via intranasal/subq. For sourcing and quality-control use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Is Selank safe during pregnancy or breastfeeding?

Selank, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a Selank Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified Selank and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect lasts hours; plasma short
WADA: Not on prohibited list
FDA: Unapproved (approved in Russia)
Research: Russian clinical trials in GAD

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for Selank

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised